OCA
MLYS icon

Octagon Capital Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Octagon Capital Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-600,000
Closed -$7.27M – 42
2024
Q3 		$7.27M Hold
600,000
– – 1.13% 24
2024
Q2 		$7.02M Buy
600,000
+50,000
+9% +$630K 1.1% 25
2024
Q1 		$7.1M Buy
+550,000
New +$6.79M 0.85% 33

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Octagon Capital Advisors's MLYS Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Mineralys Therapeutics (MLYS) in Q4 2024, closing a stake of 600,000 shares — an estimated $7.27M sold.

Octagon Capital Advisors first reported a position in MLYS in Q1 2024 and held it in 3 quarters. The position peaked at $7.27M in Q3 2024. 108 funds tracked by Wall St. Rank hold MLYS as of Q4 2024.

  • Octagon Capital Advisors reported no remaining Mineralys Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 600,000 Mineralys Therapeutics shares in Q4 2024, an estimated $7.27M.
  • Octagon Capital Advisors first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 3 quarters.
  • Octagon Capital Advisors's Mineralys Therapeutics position peaked at $7.27M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.